HDAC6 is upregulated in corneal diseases and causes ENKD1 deacetylation at lysine 98. Deacetylation of ENKD1 blocks its ...
Eight months after announcing the $18.5 million first tranche of its series A, Augustine Therapeutics has closed the ...
Pharmaceutical Technology on MSN7d
Augustine secures $85m to advance Charcot-Marie-Tooth candidateAGT-100216 will now enter a Phase I/II proof-of-concept clinical trial for CMT disease, with patient enrolment set to begin ...
Augustine Therapeutics has raised €78 million ($85 million) in first-round funding for a pipeline headed by a candidate for ...
The spending has enabled the 81-year-old business to establish fully integrated capabilities spanning the entire drug lifecycle and world-leading expertise in HDAC6 biology. CKD is developing non ...
Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round Novo Holdings and Jeito Capital co-led the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback